Europe Diabetic Foot Ulcer Treatment Market
No. of Pages: 186 | Report Code: TIPRE00024694 | Category: Life Sciences
No. of Pages: 186 | Report Code: TIPRE00024694 | Category: Life Sciences
The European diabetic foot ulcer market is divided into Germany, the UK, France, Italy, and Spain. Countries such as Germany and UK are expected to be the most significant contributor to market growth in the region. In contrast, countries such as France, Italy, and Spain, are expected to have growth opportunities for the diabetic foot ulcer market due to the rising prevalence of diabetes in European countries such as the UK, France, and Italy. In addition, the developments in the healthcare systems are likely to demand the propel the growth of the market. Also, the developments by market players and increasing numbers of healthcare facilities may offer vital growth opportunities for market growth. The Germany dominated the Europe market. The prevalence of diabetes is more in Germany which is associated with significant health consequences for the people, and eventually, it results in high medical costs for the society. The prevalence of diabetes is increasing among all ages in the European Region, majorly due to increase in overweight & obesity, unhealthy diet and physical inactivity. According to the International Diabetes Federation (IDF) Europe, in 2017, there were 7.476.800 cases of diabetes in Germany. Moreover, approximately Further 2,30,000 new diabetic foot ulcer cases are recorded in Germany each year. In addition, the rise in the aging population is likely to contribute to the growth of the market as the aging population is more likely to suffer from diabetes. As per aarpinternational.org, Germany is one of five "super-aged" societies worldwide and will continue to grow. By 2050, one-third of its population will be 65 years or older. Therefore, the market is likely to show significant growth in the forecast period due to the factors mentioned above.
In case of COVID-19, Europe is highly affected specially France. Short-term impacts of the COVID-19 pandemic include demand changes, revision in the regulatory process, changes in the research and development process, and the shift towards telecommunication and telemedicine. Moreover, the slowdown in market growth, delay in product approval, adoption of the self-sufficient pharm-production supply chain, and changes in the trend in consumption of health-market products and ethical dilemmas could be anticipated as long-term impacts of the COVID-19 pandemic on the pharmaceutical sector in both global and local levels. Various companies have undergone severe losses in the last quarter of 2019 and have negatively impacted the year 2020. As to control the spread of disease, countries have imposed complete lockdown. The lockdown has resulted in slower economies due to closed trades and business. Lockdown in France has caused delays in the raw material used for wound care products. However, companies like Molnlycke has reported 2.1% growth in their wound care sales. Company has utilized telehealth solution practices by providing education to professionals and clinicians in this business. The diabetic foot ulcer treatment market in Europe is expected to present steady growth post pandemic period. As the vaccination drives progress the healthcare system in Europe will get normalized and start focusing on wound care practices. This is expected to gradually increase the demand for diabetic foot ulcer products in Europe.
Strategic insights for the Europe Diabetic Foot Ulcer Treatment provides data-driven analysis of the industry landscape, including current trends, key players, and regional nuances. These insights offer actionable recommendations, enabling readers to differentiate themselves from competitors by identifying untapped segments or developing unique value propositions. Leveraging data analytics, these insights help industry players anticipate the market shifts, whether investors, manufacturers, or other stakeholders. A future-oriented perspective is essential, helping stakeholders anticipate market shifts and position themselves for long-term success in this dynamic region. Ultimately, effective strategic insights empower readers to make informed decisions that drive profitability and achieve their business objectives within the market.
| Report Attribute | Details |
|---|---|
| Market size in 2021 | US$ 1,213.31 Million |
| Market Size by 2028 | US$ 2,011.59 Million |
| Global CAGR (2021 - 2028) | 7.5% |
| Historical Data | 2019-2020 |
| Forecast period | 2022-2028 |
| Segments Covered |
By Type
|
| Regions and Countries Covered | Europe
|
| Market leaders and key company profiles |
The geographic scope of the Europe Diabetic Foot Ulcer Treatment refers to the specific areas in which a business operates and competes. Understanding local distinctions, such as diverse consumer preferences (e.g., demand for specific plug types or battery backup durations), varying economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved areas or adapting their offerings to meet local demands. A clear market focus allows for more effective resource allocation, targeted marketing campaigns, and better positioning against local competitors, ultimately driving growth in those targeted areas.
The Europe diabetic foot ulcer treatment market is expected to grow from US$ 1,213.31 million in 2021 to US$ 2,011.59 million by 2028; it is estimated to grow at a CAGR of 7.5% from 2021 to 2028. Growing use of 3d printing in wound care management is expected to surge the market. Skin tissue damage caused by various indications due to diabetes, and vascular diseases poses a significant burden on healthcare systems of different countries. 3D bioprinting is an approach based on layer-based synthesis, wherein the newly generated cells and cell-based materials can be dispensed to mimic native tissues. Though the technology is still in its early phase, 3D printing has a potential to revolutionize the wound care industry. Many companies are involved in developing new products involving ion-release biomaterials that will promote angiogenesis for dermal regeneration. In addition, 3D bioprinting is helping in patching large wounds that are hard to heal with standard techniques. For instance, in September 2019, AngioDerm, a project focused on regenerative medicine, received a European grant of US$ 822,000 to provide a solution for dermal regeneration for helping patients with ulcers or major burns that fail to heal. The funding was announced for five European institutions and companies working in collaboration on the project. Thus, the use of 3D bioprinting technologies in ulcer or wound treatments is likely to emerge as a prominent trend in the Europe diabetic foot ulcer treatment market in the coming years.
In terms of type, the advanced wound care dressings segment accounted for the largest share of the Europe diabetic foot ulcer treatment market in 2020. In terms of ulcer type, the neuro-ischemic ulcers segment held a larger market share of the Europe diabetic foot ulcer treatment market in 2020. Further, the hospitals segment held a larger share of the Europe diabetic foot ulcer treatment market based on end user in 2020.
A few major primary and secondary sources referred to for preparing this report on the Europe diabetic foot ulcer treatment market are company websites, annual reports, financial reports, national government documents, and statistical database, among others. Major companies listed in the report are 3M; B. Braun Melsungen AG; Cardinal Health Inc; Coloplast Group; ConvaTec Group Plc; Kerecis; Medline Industries, Inc.; MiMedx; Mölnlycke Health Care AB.; Organogenesis Inc.; Smith & Nephew; and URGO.
The Europe Diabetic Foot Ulcer Treatment Market is valued at US$ 1,213.31 Million in 2021, it is projected to reach US$ 2,011.59 Million by 2028.
As per our report Europe Diabetic Foot Ulcer Treatment Market, the market size is valued at US$ 1,213.31 Million in 2021, projecting it to reach US$ 2,011.59 Million by 2028. This translates to a CAGR of approximately 7.5% during the forecast period.
The Europe Diabetic Foot Ulcer Treatment Market report typically cover these key segments-
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the Europe Diabetic Foot Ulcer Treatment Market report:
The Europe Diabetic Foot Ulcer Treatment Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
The Europe Diabetic Foot Ulcer Treatment Market report is valuable for diverse stakeholders, including:
Essentially, anyone involved in or considering involvement in the Europe Diabetic Foot Ulcer Treatment Market value chain can benefit from the information contained in a comprehensive market report.
Office No. 1011, First floor, Farena Corporate Park, Magarpatta-Mundhwa road, Pune - 411028, Maharashtra, India
UK+442030260021, US:+16467917070
sales@businessmarketinsights.com
Get Free Sample For Europe Diabetic Foot Ulcer Treatment Market
